← Back to Search

Autologous Blood Patch for Lung Cancer

N/A

Waitlist Available

Led By Christopher Seder, MD

Research Sponsored by Rush University Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients who underwent elective wedge resection, segmentectomy, lobectomy, or bilobectomy for suspected non-small cell lung cancer

Patients who have an air leak on the morning of postoperative Day 3

Must not have

Women who are pregnant

Age ≤ 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 30 days

Awards & highlights

No Placebo-Only Group

Summary

This trial examines whether ABP is effective in preventing a prolonged air leak after lung resection for cancer.

Who is the study for?

This trial is for adults over 18 who had lung cancer surgery and have an air leak on the third day after their operation. It's not for those who had more extensive surgeries like pneumonectomy, or women who are pregnant.

What is being tested?

The study tests if using a patient's own blood to create a patch (ABP) can prevent leaks in the lungs after cancer surgery. Patients will either get this new treatment or the usual care, and researchers will compare how well each works.

What are the potential side effects?

While specific side effects of ABP aren't detailed, it may include discomfort at the blood draw site, infection risk, and potential breathing issues related to procedure complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I had surgery to remove part of my lung for suspected lung cancer.

Select...

I have an air leak from my surgery site on the third day after surgery.

Select...

I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am currently pregnant.

Select...

I am 18 years old or younger.

Select...

I have had surgery to remove a lung, part of a lung, chest wall, diaphragm, or had surgery on both sides of my chest.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 30 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 30 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

30-day Mortality

Hospital Length of Stay

In hospital mortality

+2 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Autologous Blood PatchExperimental Treatment1 Intervention

60-120ml of patient's blood will be drawn and inserted into patient's chest tube. A minimum of 60ml of blood is required, with the optimal amount of blood being 120ml.

Group II: Standard of Care (Per physician)Active Control1 Intervention

Chest tube remains intact without blood patch.

0 / 6Eligibility criteria met